Issue 12, 2024

Non-viral vector-based genome editing for cancer immunotherapy

Abstract

Despite the exciting promise of cancer immunotherapy in the clinic, immune checkpoint blockade therapy and T cell-based therapies are often associated with low response rates, intrinsic and adaptive immune resistance, and systemic side effects. CRISPR-Cas-based genome editing appears to be an effective strategy to overcome these unmet clinical needs. As a safer delivery platform for the CRISPR-Cas system, non-viral nanoformulations have been recently explored to target tumor cells and immune cells, aiming to improve cancer immunotherapy on a gene level. In this review, we summarized the efforts of non-viral vector-based CRISPR-Cas-mediated genome editing in tumor cells and immune cells for cancer immunotherapy. Their design rationale and specific applications were highlighted.

Graphical abstract: Non-viral vector-based genome editing for cancer immunotherapy

Article information

Article type
Review Article
Submitted
24 fev 2024
Accepted
25 apr 2024
First published
08 may 2024

Biomater. Sci., 2024,12, 3068-3085

Non-viral vector-based genome editing for cancer immunotherapy

T. Fang and G. Chen, Biomater. Sci., 2024, 12, 3068 DOI: 10.1039/D4BM00286E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements